

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-6. (Canceled)
7. (Currently amended) A reagent that binds CD30, wherein the reagent is (1) an antibody produced by the cell DSZ1 stored at the German Microorganisms Collection (DSM) under the number DSM ACC2548; (2) a humanized version of the antibody of (1); or (3) a binding fragment of either the antibody of (1) or the humanized antibody of (2) ~~wherein the humanized antibody and the fragment bind CD30 at the same epitope as the antibody produced by the cell DSZ1 stored at the DSM under the number DSM ACC2548.~~
8. (Withdrawn, previously presented) The reagent of claim 7, which is linked to a toxin and/or a marking.
9. (Currently amended) The reagent of Claim 8 7, linked peptidically or *via* a linker molecule to a molecule selected from the group consisting of a toxic protein, an enzyme, and a proenzyme.
10. (Withdrawn, previously presented) The reagent of Claim 9, wherein the toxic protein is a ribosome-inactivating protein.
11. (Previously presented) The reagent of Claim 9, wherein the enzyme is a phosphodiesterase.
12. (Withdrawn, previously presented) The reagent of Claim 9, linked directly or *via* a linker molecule covalently or conjugated with a radioactive isotope.

13. (Withdrawn, previously presented) The reagent of Claim 12, wherein the radioactive isotope is selected from the group consisting of indium, iodine, yttrium, technetium, rhenium, copper and lutetium.

14. (Withdrawn, previously presented) The reagent of claim 8, linked directly or *via* a linker molecule covalently or conjugated with a photoactivatable compound.

15-17. (Canceled)

18. (Previously presented) An isolated cell, stored at the DSM under the no. DSM ACC2548.

19. (Withdrawn, previously presented) A method for diagnosing CD30-positive tumors and inflammatory diseases, comprising the steps of: (a) contacting a sample from a test person with a reagent of claim 7; and (b) detecting the binding of the reagent with the sample, wherein the binding indicates the presence of a CD30-positive tumor or an inflammatory disease.

20. (Canceled)

21. (Withdrawn, previously presented) A method of treating a patient having a CD30-positive tumor, an inflammatory disease, an inflammatory-allergic disease, and/or an autoimmune disease, comprising dispensing the reagent of claim 7.

22. (Withdrawn, previously presented) The method of Claim 21, wherein the tumor is a lymphoma or embryonal carcinoma.

23. (Canceled)

24. (Withdrawn, previously presented) The method of claim 22, wherein the lymphoma is selected from the group consisting of a Hodgkin's lymphoma, an anaplastic large-cell lymphoma, an acute form of adult T-cell leukemia, and a lymphomatous form of adult T-cell leukemia.

25. (Withdrawn, previously presented) The method of claim 21, wherein 10 to 1000 mg/m² body surface of the reagent is dispensed.

26. (Withdrawn, previously presented) The method of Claim 25, wherein 20 to 400 mg/m² body surface of the reagent is dispensed.

27. (Withdrawn, previously presented) The method of claim 21, wherein the reagent is dispensed intravenously.

28. (Withdrawn, previously presented) A method of making a composition for the suppression or avoidance of a rejection reaction and/or a graft-versus-host reaction in the transplantation of organs, bone marrow or stem cells comprising incorporating the reagent of claim 7 into the composition.

29. (Previously presented) A composition comprising the reagent of claim 7.

30. (Previously presented) A kit for diagnosing CD30-positive neoplasies and inflammatory diseases, comprising the reagent of claim 7 and instructions for use for the reagent.

31. (Previously presented) The method of claim 19, wherein step (a) is carried out *in vitro*.

32. (Previously presented) The method of claim 19, wherein step (a) is carried out *in vivo*.

33. (Previously presented) The method of claim 32, wherein step (b) comprises scintigraphy.